Information about the use and accuracy of breast cancer tests is lacking

A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin). Published in the 15 November issue of Cancer, a peer-reviewed journal of the American Cancer Society, the review suggests that many breast cancer patients who may benefit from trastuzumab are not receiving it, and that some women receiving the drug have never been tested for the receptor it targets...

Read the whole article on

More from